Vimta Labs Limited has informed the Exchange about Investor Presentation
Vimta Labs Limited Registered Office: 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F : +91 40 2726 3657
VLL\SE\046\2025-26 Date: 17.07.2025
B S E Limited, P J Towers, Dalal Street, Mumbai: 400001. Scrip Code No.524394
Dear Sir/Madam,
Sub: Investor Presentation –Q1 results – FY 2025-26
National Stock Exchange of India Limited, “Exchange Plaza”, Bandra, Kurla Complex, Bandra (E),Mumbai – 400051. Trading Symbol: VIMTALABS
Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) we are enclosing herewith the Investor Presentation. Further, pursuant to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., https://vimta.com/investor- presentation/
This is for your information and necessary records.
For VIMTA LABS LTED
Sujani Vasireddi
Company Secretary
Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E: mdoffice@vimta.com LIRL : www.vimta.com CIN : L24110TG1990PLC011977
INVESTOR PRESENTATION
Q1 FY26
1 1
Disclaimer
The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.
This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.
No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.
2
Table Of Contents
• Q1 FY26 Earnings
• Company Overview
•
Industry Landscape
• Our Competitive Advantage
• Way Forward
3
Section 01
Q1 FY26 Earnings
• Q1 FY26 Highlights
•
Key Metrics: Q1 FY26 and FY25
• Profit & Loss Statement
•
•
Financial Track Record
Shareholding Pattern
4 4
Q1 FY26 Highlights
Rs 993 Mn
Total Income
Rs 4.2
EPS
Rs 354 Mn Margin 35.7%
EBITDA
Rs 241.2 Mn
CAPEX (Cash Outflow)
Rs 253 Mn
PBT
Rs 189 Mn Margin 19.0%
PAT
5
Key Metrics: Q1 FY26
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
31.4% YoY
`
33.1% YoY
35.2%
36.1%
35.7%
756
961
993
266
347
354
35.9% YoY
19.1%
19.0%
18.4%
139
183
189
200
175
150
125
100
75
50
25
-
19%
19%
19%
19%
18%
18%
18%
5
0
3.1
4.1
4.2
Q1FY25
Q4FY25
Q1FY26
Q1FY25 Q4FY25 Q1FY26
Q1FY25 Q4FY25 Q1FY26
Q1FY25 Q4FY25 Q1FY26
6
Key Metrics: FY25
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
19.1% YoY
29.1% YoY
33.4%
36.2%
2,923
FY24
3,482
FY25
977
FY24
1,262
FY25
725
700
675
650
625
600
575
550
525
500
475
450
425
400
375
350
325
300
275
250
225
200
175
150
125
100
75
50
25
-
36.8% YoY
16.7%
488
FY24
20%
19%
19%
18%
18%
17%
17%
16%
16%
15%
19.2%
668
FY25
11.0
FY24
15.1
FY25
7
Profit & Loss Statement
Particulars (₹ Mn)
Revenue from Operations
Other Income
Total Income
Material and Testing Costs
Cost of lab setup
Changes in inventories of work-in-progress
Employee benefits expense
Other expenses
Total Expenses
EBIDTA
EBIDTA (%)
Finance costs
Depreciation expense
Profit before tax
PBT (%)
Tax
Profit for the year
PAT (%)
Basic EPS (INR)
Q1 FY26
Q1 FY25
YoY (%)
Q4 FY25
QoQ(%)
976
17
993
188
0
0
278
172
639
354
35.7%
3
99
253
25.4%
64
189
19.0%
4.2
944
16
961
182
0
0
273
160
614
347
36.1%
4
92
250
26.1%
67
183
19.1%
4.1
749
7
756
143
0
0
224
122
489
266
35.2%
5
80
182
24.0%
43
139
18.4%
3.1
3.4%
2.2%
0.9%
3.1%
2.4%
31.4%
33.1%
39.1%
35.9%
33.8%
8
Financial Track Record
TOTAL INCOME (₹ Mn)
PROFITABILITY (₹ Mn)
EBITDA & EBITDA Margin
PAT & PAT Margin
1,837 2,115 2,797 3,216 2,923 3,482
330
538
817
984
977
1,262
11.2% CAGR
25%
18%
29%
31%
33%
36%
25.1% CAGR
4%
68
10%
214
19%
17%
15% 15%
413
482 488 668
46.3% CAGR
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
Total Revenue
EBIDTA
EBIDTA Margin
PAT
PAT Margin
BALANCE SHEET RATIOS
RoE (%)
RoCE (%)
Debt to Equity
Total Capex
4%
11%
18%
17%
15%
18%
15% 18% 25% 22% 19% 23%
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
0.2
0.1
0.0
0.16
0.16 0.08 0.05 0.06 0.02
166
357
450
492
763
791
FY20 FY21 FY22 FY23 FY24 FY25
FY20
FY21
FY22
FY23
FY24
FY25
1. Financial numbers for the period FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business 2. CAGR for the period FY20-FY25
9
Shareholding Pattern
Shareholding as on 30th June 2025
Others 58.4%
Promoters 36.7%
DII 1.4%
FII 3.5%
Share Information as on 30th June 2025
NSE Ticker
BSE Ticker
Market Cap (INR Cr)
% free-float
Free-float market cap (INR Cr)
Total Debt (INR Mn)
Cash & Cash Equivalents (INR Mn)
VIMTALABS
524394
2,001.19
63.30%
1,267.35
70.3
150.1
Shares Outstanding
4,45,05,568
3M ADTV (Shares)*
1,78,368.29
3M ADTV (INR Cr)*
Industry
16.23
TIC
Source: NSE & BSE
#Cash and Cash equivalents includes other bank balances
10
Section 02
Company Overview
•
Vimta at a Glance
• Our Journey
• Our Offerings
• Geographical Presence
• Management
11 11
Vimta at a Glance
Established in 1984, VIMTA is one of India’s most renowned companies for contract research and
testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable
services and vast experience. The company’s broad capabilities span across biologics, small molecules,
agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and
environment testing.
41+ Years Of experience in CRTO industry
1,300+ Dedicated Multi- Disciplinary Team
600,000+ Sq. Ft. of Ultra- modern lab spaces
10 Labs and Offices across India
~100 Successful Regulatory Audits
12
Our Journey
Infrastructure
People
Investment
Capabilities
Revenues
2024
600,000+ ft2
1300+
492 M
Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing
3,216 M
2015
400,000+ ft2
1000+
580 M
Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing
1,073 M
2006
200,000+ ft2
600+
992 M
Clinical Research; Environment; Analytical Testing – Food & Pharma
542 M
1992
50,000+ ft2
150+
85 M
Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research
16 M
1984
500 ft2
6
200,000
Minerals & ores; Metals; Rice bran oil testing
156,000
1. Investment & Revenues in INR 2. Investments depicted may have spread across more than the denoted year
13
Our offerings
Drug discovery and development services
Food & Agri Testing
Electronics & Electricals Testing
Environment Testing & Consultancy
14
1. Drug discovery and development services
Offerings
Pharma Analytical
Clinical Research
Preclinical Research
Industry
Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health
Pharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality Chemicals
Accreditations & Regulatory Approvals
Services
DCA, USFDA, WHO, EMA, DRAs of Ukraine, Turkey
CDSCO, USFDA, WHO, MHRA, NPRA, and European DRAs
OECD-GLP, CCSEA, DSIR, AAALAC
Wide range of analytical services
• E&L studies • Stability testing • Method
development
• Validations • Genotoxic impurities
• Elemental analysis In vitro studies • • Physical
Characterisation
• Dissolution Testing
• Microbiology •
Immunogenicity studies
• Characterization • Bioassays
• BA/BE Studies
• Bioanalytical
• Clinical Trials (Phase I to
IV)
• Clinical End Point
Studies
• Claim Studies
• Comprehensive in vitro, ex vivo and in
vivo studies • ADME, and PK •
IND enabling packages (genetic toxicology, safety pharmacology, general toxicology, & toxicokinetic studies).
• Chronic toxicology, reproductive toxicology, neurotoxicology, immunotoxicology, and carcinogenicity
• Biowaiver and alternative to animal
studies
• Ecotoxicology, environmental fate and
metabolism studies
15
15
2. Food & Agri Testing
Industry
Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed
No. of Locations
7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida)
Accreditations & Regulatory Approvals
• FSSAI, ISO 17025, BIS, APEDA, EIC, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board • Hyderabad Lab is a National Reference Lab for Water & Beverages Testing • Mumbai Lab is a National Food Laboratory, operated for FSSAI
Services
• Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for
all agri, food, food products, water and beverages
• New product development support, validations • Shelf-life assessments • Packaging material testing • Nutraceuticals testing, method validations • Animal feed analysis • Argo-chemical (crop sciences): support for research and development, method development, validation and
testing for regulatory submissions in India, Europe, South America, Japan, Southeast Asia
16
16
3. Electricals & Electronics Testing & Certification
Industry
Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries
No. of Locations
1 (Hyderabad)
Accreditations & Regulatory Approvals
ISO 17025, TEC
• • BIS & NABCB (of Emtac Laboratories Pvt Ltd., fully owned subsidiary)
Services
• EMI/EMC testing • Radio Frequency testing • Environmental & reliability testing • Mechanical & electrical safety testing • Performance testing • Product Certification • CE marking
17
17
4. Environment Testing & Consultancy Services
Industry
Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc.
No. of Locations
4 (Hyderabad, Chennai, Kolkata and Noida)
Accreditations & Regulatory Approvals
Services
• MoEF, ISO 17025, QCI/NABET, OSHAS 45000
• Post project monitoring • • Advanced testing & tailor-made services (CEMS validation, PG for pollution equipment, Dioxins, Furans,
Industrial hygiene & Indoor air
Industrial Gas, VOC as per LEED and EPA)
• Offshore monitoring • SIA & hydrogeological studies • EHS audits, Hazardous waste study, Life cycle assessment • Due diligence studies • Green audit, Metrological studies • Noise, air, traffic modelling etc.
18
18
Geographical Presence
Food
Environment
Hyderabad
Ahmedabad
Noida
Mumbai (NFL)
Nashik
Bengaluru
Nellore
Hyderabad
Chennai
Noida
Kolkata
Electrical and Electronics
Hyderabad
Hyderabad (Headquarters)
Food
Electronics & Electrical
Pharma
Environment
19
Key Management Team
S P Vasireddi Executive Chairman
Harita Vasireddi Managing Director
Sreenivas Neerukonda Executive Director
• Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.
• Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.
• Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.
• Her Core competencies include
management & driving organizational adaptability and development, quality management systems, and risk management.
•
She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India
•
Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal-oriented performance.
• He holds an MBA in
Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.
Harriman Vungal Executive Director - Operations
• Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.
• He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.
• He holds D. Tech in Electronics
from Toronto, Canada.
Siva Kambhampati Chief Financial Officer
•
Siva is a seasoned finance professional with a strong academic foundation. He is a CA and secured 63rd rank in cost accountancy. With over 16 years on experience in the engineering and pharmaceutical industries, he brings diverse expertise in strategic financial planning & management, product costing & pricing, and treasury management.
He has previously worked at Artson engineering Ltd. (A TATA Enterprise, Hyderabad as a CFO.
20
Section 03
Industry Landscape
• Market Opportunity
•
Factors Driving Industry Growth
21 21
Markets Opportunity (Global)
Pharmaceutical Analytical Testing
Preclinical
Food Testing
Environment Testing
Electronics Testing
14,580
14,340
36,250
9,320
9,740
)
n M D S U
(
25,330
7,430
3,990
6,250
2,550
2025 | 2030
2024 | 2034
2025 | 2030
2025 | 2030
2023 | 2030
22
l
a b o G
l
Markets Opportunity (Indian)
Pharmaceutical Analytical Testing
Preclinical
Food Testing
Environment Testing
Electronics Testing
309
394
1,799
460
)
n M D S U
(
185
211
832
293
100
50
2025 | 2030
2024 | 2030
2024 | 2033
2024 | 2030
2021 | 2028
23
i
n a d n
I
Factors Driving Industry Growth
•
Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry
• Specialized knowledge, skills and
testing tools that CROs can provide
• Growing international food
regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third- party inspection & testing
Drug Discovery & Development
Electrical & Electronics Testing
• Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives
• Green push by Government for
electrical vehicles
Food Testing
Environment Testing
•
Increase in regulations to address the growing concerns of air, water and soil contamination
24
Section 04
Our Competitive Advantage
• Our Position in the CRTO Landscape
• Our Strength
25 25
Our Position in the CRTO Landscape
Pharma Analytical
Clinical Research
Electronics & Electricals
• #1 in India
• Among the most reputed CROs in
• Customers – 95% of top 50 in India
• 38% revenues from overseas
India
• 75% of revenues from overseas
•
leading provider of EMI/EMC testing services in India
Food Testing
Preclinical
Environment
• #1 in India • Serving 16 of India’s top 20 food
companies
• The only private EU commission
approved lab in India
• Amongst Top 5 in India
• Among top 5 in India
• Customers – PSUs, large
corporations across industries
26
26
Our Strengths
Infrastructure
Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium
Innovations
Continuous addition of services and evolving excellence
Knowledge
Multi-disciplinary, knowledgeable, skilled and trained manpower
Customer Centricity
Compliance
Technology
Long term partnerships with customers
Strong culture of quality and compliance Long & successful regulatory track record – cGMP, GLP, GCP
Wide range of state-of- the-art technologies and scalable capacities
27
Section 05
Way Forward
• Our Key Growth Drivers & Strategies
28 28
Our Key Growth Drivers & Strategies
Favourable markets
Core business strategies
Core operational strategies
Best practices
✓ Growth momentum
✓ Capacity expansions
✓ Operational excellence
✓ Good corporate governance
in markets
✓ Growing demand
for safe & quality - drugs, food, diagnostics, electronics & clean environment
✓ Service innovations
✓ Hiring right talent
✓ Risk management
✓ Penetration into new markets
✓ Quality & compliance culture
✓ Listening to customers’ needs
✓ Customer partnerships
✓ Cutting edge technologies
✓ Continuous learning
29
THANK YOU
Vimta Labs Ltd.
Siva Kambhampati | Chief Financial Officer
Siva.Kambhampati@vimta.com
Registered Office
#142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051
Ernst & Young
Siddesh Chawan
Advait Bhadekar
NSE: VIMTALABS
ISIN: INE579C01029
Siddesh.Chawan@in.ey.com
Advait.Bhadekar@in.ey.com
BSE: 524394
Website: www.vimta.com
30